Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials
Among high-risk post-PCI patients on ticagrelor/prasugrel, discontinuing aspirin within 3 months reduces bleeding without an ischemic trade-off versus DAPT. Immediate aspirin noninitiation or cessation should be avoided; timing should be individualized to bleeding and ischemic risk. PROSPERO: CRD420251167706.
Authors
- Safi Ullah Khan
- Klaudyna Grzelakowska (ORCID: https://orcid.org/0000-0001-6175-2191)
- Michael E. Farkouh (ORCID: https://orcid.org/0000-0002-8095-0246)
- Julia M. Umińska (ORCID: https://orcid.org/0000-0003-2309-2369)
- Giuseppe Talanas (ORCID: https://orcid.org/0000-0003-4317-9728)
- Dean J. Kereiakes
- Eliano P. Navarese
- Jacek Kubica
- Udaya Tantry
- Timothy D. Henry
- Young-Hoon Jeong
- Paul Gurbel
- Kevin Bliden
Institutions
- University of Sassari (IT)
- Sinai Hospital (US)
- Nicolaus Copernicus University (PL)
- Heart Hospital Baylor Plano (US)
- Sinai Health System (US)
- Christ Hospital (US)
- Link Campus University (IT)
- Chung-Ang University (KR)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1371/journal.pmed.1004995
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00